Archives
Epinephrine Bitartrate: Non-Selective Adrenergic Receptor...
Epinephrine Bitartrate: Non-Selective Adrenergic Receptor Agonist for Cardiovascular and Neurobiology Research
Executive Summary: (-)-Epinephrine (+)-bitartrate is a high-purity, non-selective adrenergic receptor agonist activating α₁/α₂ and β₁/β₂/β₃ receptors with EC₅₀ values of 5–10 nM in vitro (APExBIO, product page). It is used in cardiovascular, sympathetic nervous system, and neurobiology research to model vasoconstriction, heart rate modulation, and bronchodilation. Standard in vivo dosing in canines ranges from 0.15–0.3 mg intramuscularly or 2–20 mg intranasally (Dretchen et al., 2020). The compound is highly soluble in water (≥22.9 mg/mL) and DMSO (≥16.66 mg/mL), with storage at -20°C recommended. Clinical applications include emergency treatment of anaphylactic shock and acute bronchial asthma exacerbations (APExBIO).
Biological Rationale
Epinephrine, also known as adrenaline, is a catecholamine endogenously released by the adrenal medulla. It is a primary mediator of the sympathetic nervous system and plays a pivotal role in the 'fight-or-flight' response. Its physiological effects include vasoconstriction, increased heart rate (chronotropy), increased contractility (inotropy), bronchodilation, and inhibition of allergic mediator release (APExBIO). These actions are mediated through adrenergic receptors distributed throughout the cardiovascular and respiratory systems. The non-selective activation profile of (-)-Epinephrine (+)-bitartrate makes it a reference standard for dissecting adrenergic signaling pathways in cell-based and translational research (related article). This article extends previous coverage by mapping quantitative receptor activation thresholds and pharmacokinetic benchmarks in experimental models.
Mechanism of Action of (-)-Epinephrine (+)-bitartrate
The compound acts as a non-selective adrenergic agonist, binding to α₁, α₂, β₁, β₂, and β₃ receptors. The EC₅₀ values are approximately 10 nM for β₁, 5 nM for α₁, and 8 nM for β₂ under standard in vitro conditions (aqueous buffer, 37°C, pH 7.4) (APExBIO). Upon receptor engagement:
- α₁-adrenergic activation induces smooth muscle contraction, leading to vasoconstriction and increased blood pressure.
- β₁-adrenergic stimulation increases heart rate and myocardial contractility.
- β₂-adrenergic activation relaxes bronchial smooth muscle, resulting in bronchodilation.
These effects are dose-dependent and reversible. The compound is used in vitro at 1 nM to 10 μM to modulate cell signaling pathways, such as cAMP and calcium flux.
Evidence & Benchmarks
- In canines, intramuscular dosing at 0.15–0.3 mg and intranasal dosing at 2–20 mg produce rapid increases in plasma epinephrine and distinct heart rate effects (Dretchen et al., 2020).
- Intranasal administration at 5 mg yields a plasma concentration of 1.68 ± 0.65 ng/mL at 1 minute, significantly higher than intramuscular 0.3 mg (0.21 ± 0.08 ng/mL, p = 0.03) (Table 1, Dretchen 2020).
- The compound is highly soluble in water (≥22.9 mg/mL) and DMSO (≥16.66 mg/mL) but insoluble in ethanol (APExBIO).
- Adrenergic receptor activation modulates cAMP, calcium signaling, and downstream kinase pathways in cardiovascular and neurobiology assays (related article).
- Immediate epinephrine administration is the standard of care for anaphylaxis and acute bronchial asthma (Dretchen 2020).
Applications, Limits & Misconceptions
(-)-Epinephrine (+)-bitartrate is widely employed for:
- Cardiovascular disease research, including hypertension, arrhythmia, and heart failure models.
- Sympathetic nervous system and neurobiology studies targeting adrenergic signaling (related article). This article updates prior work by detailing pharmacodynamic and solubility parameters relevant for bench-to-bedside translation.
- Emergency treatment of anaphylactic shock and acute asthma, as well as adjuvant use in local anesthesia to prolong effect and reduce bleeding.
- Cell signaling assays quantifying receptor-specific effects and pharmacological profiling.
Common Pitfalls or Misconceptions
- Not effective in patients with pheochromocytoma or hyperthyroidism; contraindicated due to risk of crisis (APExBIO).
- Overdose can cause arrhythmias, severe hypertension, or myocardial ischemia; careful titration and monitoring required (Dretchen 2020).
- Clinical efficacy is route- and species-dependent; dosing must be empirically validated for each model.
- Long-term storage of solutions is discouraged due to instability and diminished potency.
- Insoluble in ethanol; improper solvent selection can lead to precipitation and loss of bioactivity.
Workflow Integration & Parameters
For in vitro work, (-)-Epinephrine (+)-bitartrate is typically dissolved in water or DMSO to concentrations up to 22.9 mg/mL and 16.66 mg/mL, respectively. Working concentrations for cell-based assays range from 1 nM to 10 μM. In vivo dosing must account for species, route, and experimental endpoint; canine studies have validated 0.15–0.3 mg IM and 2–20 mg IN (Dretchen 2020). Solutions should be freshly prepared, and storage at -20°C is required for powder. The B1358 kit from APExBIO offers traceability and batch-specific documentation (product link). For workflow optimization, see Epinephrine Bitartrate: the gold-standard agonist for signaling pathway research, which focuses on purity and solubility; this article adds new in vivo performance and safety data.
Conclusion & Outlook
(-)-Epinephrine (+)-bitartrate is a validated, non-selective adrenergic receptor agonist with broad research and clinical applications. Its pharmacodynamic and pharmacokinetic properties underpin its utility as a reference compound in cardiovascular, neurobiology, and sympathetic nervous system studies. As highlighted by recent canine studies, route of administration, dosing, and formulation critically influence outcomes, supporting the need for detailed experimental planning. Continued development of alternative delivery routes and new formulations may further expand the translational impact of this compound in both research and clinical settings (Dretchen 2020).